Skip to content
Inciteful Med
Resources About us Ask a Question

Does Scleroderma or Autoimmune Disease Cause Gastroparesis?

Published: | Updated:

Yes, autoimmune diseases like scleroderma, lupus, and Sjögren's can cause gastroparesis. These conditions damage the stomach's nerves and muscles, preventing normal digestion. While active inflammation may improve with immune therapies, permanent muscle scarring requires targeted symptom management.

Key Takeaways

  • • Autoimmune conditions like scleroderma and lupus can cause gastroparesis by heavily damaging the stomach's nerves and muscles.
  • • Scleroderma leads to a buildup of stiff scar tissue (fibrosis) in the stomach muscle, which is often permanent.
  • • Lupus can cause gastroparesis through inflamed blood vessels (vasculitis), which may improve with targeted immune therapies.
  • • Parkinson's disease can lead to delayed gastric emptying by directly damaging the nerves that control digestion.
  • • Determining whether gastroparesis is caused by active inflammation or permanent scarring helps guide the most effective treatment plan.

Yes, autoimmune diseases and certain systemic conditions can cause gastroparesis. While diabetes or surgical complications are the most widely recognized triggers, a variety of diseases that affect the whole body—such as scleroderma, lupus, amyloidosis, and even neurological disorders like Parkinson’s disease—can disrupt how your stomach empties. Managing a complex systemic illness on top of severe digestive issues can be overwhelming, but understanding the root cause is a crucial first step.

These conditions typically cause gastroparesis by damaging either the enteric nervous system (the complex web of nerves controlling your gut) or the stomach’s smooth muscle tissue, preventing the coordinated contractions needed to digest food [1][2][3].

Autoimmune and Connective Tissue Diseases

Autoimmune diseases occur when the body’s immune system mistakenly attacks its own tissues. When this attack targets the gastrointestinal tract, it can lead to severe dysmotility.

  • Scleroderma (Systemic Sclerosis): Scleroderma is characterized by the hardening and tightening of the skin and connective tissues, but it heavily impacts internal organs. In the stomach, the disease initially damages blood vessels and nerves [4][5]. Over time, this leads to fibrosis (the buildup of stiff scar tissue) within the stomach muscle itself [3][6]. Scleroderma also causes a depletion of the interstitial cells of Cajal (ICC), which act as the electrical pacemakers of the stomach [3][6]. Interestingly, the severity of skin symptoms does not always predict how severe the stomach paralysis will be [7].
  • Systemic Lupus Erythematosus (SLE): Lupus can cause gastroparesis through vasculitis, which is the inflammation of blood vessels [1][8][9]. When the blood vessels supplying the digestive tract become inflamed, the nerves and muscles of the stomach are starved of oxygen and nutrients. Lupus can also directly damage the autonomic nerves that signal the stomach to empty [1][8].
  • Sjögren’s Syndrome: Primarily known for causing dry eyes and dry mouth, Sjögren’s is linked to general autonomic neuropathy (damage to the involuntary nerves), which can include the nerves controlling stomach emptying [10][11][12].

Can treating the autoimmune disease fix the stomach?

A common question is whether getting the underlying autoimmune condition under control will reverse the gastroparesis. The answer depends on the type of damage. If the symptoms are driven by active inflammation—such as vasculitis in lupus—treating the flare-up with targeted immune therapies (like high-dose corticosteroids or immunosuppressants) can sometimes significantly improve gastrointestinal function [13][1]. However, if the disease has already caused permanent structural changes, such as the rigid muscle scarring (fibrosis) seen in late-stage scleroderma, the damage is typically irreversible, and treatment will focus more on managing the digestive symptoms directly rather than reversing the tissue damage [4][3].

Infiltrative Diseases

  • Amyloidosis: This systemic condition occurs when abnormal proteins (amyloid fibrils) build up in organs. When these proteins infiltrate the walls of the stomach, they can disrupt the enteric nervous system and physically block the smooth muscles from contracting normally, leading to gastroparesis [3].

Neurological Conditions: Parkinson’s Disease

While not an autoimmune condition, Parkinson’s disease is a major neurological cause of gastroparesis. Parkinson’s involves the buildup of a misfolded protein called alpha-synuclein [14][15].

  • Nerve Damage, Not Muscle: Unlike scleroderma, which damages the stomach muscle, Parkinson’s primarily affects the nerves. Alpha-synuclein deposits build up directly in the enteric nervous system and the vagus nerve, disrupting the brain-to-gut signaling required for digestion [14][16][2].
  • Early Warning Sign: In some patients, characterized as having a “body-first” phenotype, gastrointestinal symptoms like delayed emptying and severe constipation can appear well before traditional motor symptoms like tremors [17][18]. The severity of the delayed gastric emptying often worsens as the disease progresses [19][20].

Paraneoplastic Syndromes (Extremely Rare)

An extremely rare secondary cause of gastroparesis is a paraneoplastic syndrome. This occurs when an individual has an underlying cancer—most commonly small cell lung cancer—and their immune system mounts an attack against the tumor [21][22].

  • Cross-Reaction: The tumor contains proteins that look identical to the proteins found on healthy nerve cells. The immune system generates antibodies (like anti-Hu or anti-CV2/CRMP5) and immune cells (T-cells) that mistakenly attack the nerves of the digestive tract [22][23].
  • T-Cell Destruction: The damage is largely driven by CD8+ T-cells (specialized immune cells) that directly destroy the enteric neurons [24][25].

Because this condition can cause a rapid, severe decline in digestion, testing for these specific antibodies may be considered if gastroparesis appears very suddenly and the person has clear risk factors for cancer, such as older age or a significant history of smoking [22]. Sudden-onset gastroparesis in young, otherwise healthy people is far more likely to be caused by a routine viral infection rather than a hidden cancer [26][27].

By understanding the exact mechanism—whether it is nerve damage from Parkinson’s, scar tissue from scleroderma, or inflammation from lupus—you can work with a coordinated care team (such as a rheumatologist or neurologist alongside your gastroenterologist) to target your overall treatment plan.

Frequently Asked Questions

Can treating my autoimmune disease cure my gastroparesis?
It depends on the type of damage causing your symptoms. If the gastroparesis is driven by active inflammation, such as inflamed blood vessels in lupus, targeted immune therapies can improve digestion. However, if the disease has already caused permanent scar tissue, treatment focuses on managing the digestive symptoms directly.
How does scleroderma cause gastroparesis?
Scleroderma damages the stomach by destroying blood vessels, nerves, and vital pacemaker cells. Over time, it causes a buildup of stiff scar tissue within the stomach muscle, which physically prevents the stomach from contracting and digesting food normally.
Can Parkinson's disease cause stomach paralysis?
Yes, Parkinson's disease frequently causes delayed stomach emptying. It occurs when abnormal proteins build up in the nervous system, disrupting the crucial brain-to-gut signals needed for normal digestion. For some patients, these severe digestive issues appear before physical tremors.
Should I be tested for cancer if my gastroparesis starts suddenly?
Sudden-onset gastroparesis can extremely rarely be a sign of cancer, known as a paraneoplastic syndrome. Testing for specific antibodies might be considered if your severe symptoms appear suddenly and you have significant risk factors for cancer, like an older age or a history of smoking.
Do my gastroenterologist and rheumatologist need to work together?
Yes, coordinating care between your gastroenterologist and other specialists like a rheumatologist or neurologist is highly recommended. Understanding if your gastroparesis is driven by active inflammation, nerve damage, or muscle scarring is crucial to creating an effective, unified treatment plan.

Questions for Your Doctor

  • • Should my rheumatologist/neurologist and gastroenterologist be actively coordinating my treatment plan to address my underlying disease and my stomach issues together?
  • • Do you believe my delayed emptying is primarily caused by active inflammation (which might respond to my autoimmune medications) or permanent scarring/nerve damage?
  • • Could any of the medications I take for my systemic condition (such as oral Parkinson's meds) be slowing down my digestion even further?
  • • If I have a connective tissue disease, should we use targeted motility testing to distinguish between nerve dysfunction and muscle fibrosis to guide my therapy?

Questions for You

  • • Did my digestive symptoms start before, during, or after the onset of my other systemic symptoms, such as joint pain, skin tightening, or tremors?
  • • Do I experience any other signs of systemic nerve dysfunction, such as feeling dizzy when standing up, changes in sweating, or unusually dry eyes and mouth?
  • • How much does my gastroparesis fluctuate? Do my stomach issues flare up at the exact same time my joint pain or skin symptoms flare up?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Clinical and therapeutical features of patients with systemic lupus erythematosus associated with gastroparesis: A systematic review.

    Carvalho JF

    European journal of rheumatology 2022; (9(1)):50-53 doi:10.5152/eurjrheum.2021.20094.

    PMID: 35110136
  2. 2

    Gastric dysmotility in Parkinson's disease is not caused by alterations of the gastric pacemaker cells.

    Heimrich KG, Jacob VYP, Schaller D, et al.

    NPJ Parkinson's disease 2019; (5()):15 doi:10.1038/s41531-019-0087-3.

    PMID: 31372495
  3. 3

    Pathophysiology of idiopathic gastroparesis and implications for therapy.

    Bekkelund M, Sangnes DA, Gunnar Hatlebakk J, Aabakken L

    Scandinavian journal of gastroenterology 2019; (54(1)):8-17 doi:10.1080/00365521.2018.1558280.

    PMID: 30638082
  4. 4

    Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches.

    Hoffmann-Vold AM, Volkmann ER

    Journal of scleroderma and related disorders 2021; (6(1)):37-43 doi:10.1177/2397198319891282.

    PMID: 35382247
  5. 5

    Gastrointestinal involvement in systemic sclerosis: diagnosis and management.

    McMahan ZH, Hummers LK

    Current opinion in rheumatology 2018; (30(6)):533-540 doi:10.1097/BOR.0000000000000545.

    PMID: 30234725
  6. 6

    Depleted interstitial cells of Cajal and fibrosis in the pylorus: Novel features of gastroparesis.

    Moraveji S, Bashashati M, Elhanafi S, et al.

    Neurogastroenterology and motility 2016; (28(7)):1048-54 doi:10.1111/nmo.12806.

    PMID: 26940535
  7. 7

    Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with Diabetes and Symptoms of Gastroparesis.

    Siraj ES, Homko C, Wilson LA, et al.

    Frontiers in endocrinology 2018; (9()):32 doi:10.3389/fendo.2018.00032.

    PMID: 29487566
  8. 8

    Lupus Vasculitis.

    Calle-Botero E, Abril A

    Current rheumatology reports 2020; (22(10)):71 doi:10.1007/s11926-020-00937-0.

    PMID: 32845454
  9. 9

    Gastrointestinal and Hepatic Disease in Systemic Lupus Erythematosus.

    Brewer BN, Kamen DL

    Rheumatic diseases clinics of North America 2018; (44(1)):165-175 doi:10.1016/j.rdc.2017.09.011.

    PMID: 29149925
  10. 10

    United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis.

    Schol J, Wauters L, Dickman R, et al.

    Neurogastroenterology and motility 2021; (33(8)):e14237 doi:10.1111/nmo.14237.

    PMID: 34399024
  11. 11

    Randomised study: effects of the 5-HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis.

    Chedid V, Brandler J, Arndt K, et al.

    Alimentary pharmacology & therapeutics 2021; (53(9)):1010-1020 doi:10.1111/apt.16304.

    PMID: 33711180
  12. 12

    Relationships between autonomic nerve function and gastric emptying in patients with autoimmune gastritis.

    Kalkan Ç, Soydal Ç, Özkan E, et al.

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2016; (26(3)):189-96 doi:10.1007/s10286-016-0353-y.

    PMID: 27059861
  13. 13

    Belimumab-induced remission in refractory lupus mesenteric vasculitis: a case report with 49-month follow-up.

    Gao WJ, Zang QF, Xu Y, Zang YS

    Frontiers in immunology 2026; (17()):1687299 doi:10.3389/fimmu.2026.1687299.

    PMID: 41859114
  14. 14

    Fatal autonomic failure due to premanifesting Parkinson's disease only diagnosed at autopsy.

    Bodi I, Hagen EM, Ingle GT, Lunn MP

    Clinical case reports 2020; (8(10)):1997-1999 doi:10.1002/ccr3.3042.

    PMID: 33088537
  15. 15

    Colonic bacterial composition in Parkinson's disease.

    Keshavarzian A, Green SJ, Engen PA, et al.

    Movement disorders : official journal of the Movement Disorder Society 2015; (30(10)):1351-60 doi:10.1002/mds.26307.

    PMID: 26179554
  16. 16

    Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice.

    Challis C, Hori A, Sampson TR, et al.

    Nature neuroscience 2020; (23(3)):327-336 doi:10.1038/s41593-020-0589-7.

    PMID: 32066981
  17. 17

    Gastric emptying time and its correlation with cardiac MIBG in body-first and brain-first subtype Parkinson's disease.

    Kim MS, Park DG, Shin IJ, et al.

    Journal of neurology 2024; (272(1)):28 doi:10.1007/s00415-024-12783-6.

    PMID: 39665845
  18. 18

    Evaluation of bidirectional gut-brain axis and anorectal function in Parkinson's disease with constipation.

    Yan Y, Tennekoon K, Eubanks A, et al.

    Neurogastroenterology and motility 2024; (36(3)):e14728 doi:10.1111/nmo.14728.

    PMID: 38105462
  19. 19

    Gastric-filling ultrasonography to evaluate gastric motility in patients with Parkinson's disease.

    Zou X, Chen X, Wen Y, et al.

    Frontiers in neurology 2024; (15()):1294260 doi:10.3389/fneur.2024.1294260.

    PMID: 38410194
  20. 20

    Bilateral Subthalamic Nucleus Deep Brain Stimulation Improves Gastric Emptying Time in Parkinson Disease.

    Wang Y, Gao P, Zhang X, et al.

    World neurosurgery 2021; (154()):e683-e688 doi:10.1016/j.wneu.2021.07.112.

    PMID: 34343688
  21. 21

    Anti-CV2/Collapsin Response Mediator Protein 5 (CRMP5) Paraneoplastic Encephalitis Induced by Small Cell Lung Cancer.

    Helgason VÞ, Qureshi PAAA, Bollineni VR, et al.

    Cureus 2023; (15(1)):e34323 doi:10.7759/cureus.34323.

    PMID: 36865958
  22. 22

    Paraneoplastic neurological syndromes: clinical presentations and management.

    Devine MF, Kothapalli N, Elkhooly M, Dubey D

    Therapeutic advances in neurological disorders 2021; (14()):1756286420985323 doi:10.1177/1756286420985323.

    PMID: 33796141
  23. 23

    Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review.

    Yan J, Chen Z, Liang Y, et al.

    The Journal of international medical research 2020; (48(12)):300060520974466 doi:10.1177/0300060520974466.

    PMID: 33305627
  24. 24

    Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review.

    Rossi S, Merli E, Rinaldi R, et al.

    Journal of neurology 2022; (269(3)):1182-1194 doi:10.1007/s00415-021-10577-8.

    PMID: 33934212
  25. 25

    Enteric Murine Ganglionitis Induced by Autoimmune CD8 T Cells Mimics Human Gastrointestinal Dysmotility.

    Sanchez-Ruiz M, Brunn A, Montesinos-Rongen M, et al.

    The American journal of pathology 2019; (189(3)):540-551 doi:10.1016/j.ajpath.2018.11.016.

    PMID: 30593823
  26. 26

    Electroacupuncture protects gastric Cajal cells by reducing macrophage pyroptosis in diabetic gastroparesis.

    Fan MW, Tian JL, Zhang SH, et al.

    World journal of diabetes 2026; (17(2)):114252 doi:10.4239/wjd.v17.i2.114252.

    PMID: 41696103
  27. 27

    Macrophages: The Missing Link in Diabetic Gastroparesis?

    Srinivasan S

    Cellular and molecular gastroenterology and hepatology 2016; (2(1)):5-6 doi:10.1016/j.jcmgh.2015.11.003.

    PMID: 28174701

This page explains the link between gastroparesis and autoimmune or neurological conditions for educational purposes. Always consult your gastroenterologist, rheumatologist, or neurologist for specific medical advice and to coordinate your treatment.

Stay up to date

Get notified when new research about Gastroparesis is published.

No spam. Unsubscribe anytime.